Drug Database
CI

ciprofloxacin

✓ Approved

Nanodaru · gyrA · Small Molecule

What is ciprofloxacin?

ciprofloxacin is a small molecule developed by Nanodaru. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyNanodaru
Drug ClassSmall Molecule
Molecular TargetgyrA, parC, , , , , ,
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Mechanism of Action

Molecular Targets

ciprofloxacin acts on 8 molecular targets:

gyrADNA gyrase subunit A (nalA, parD)
parCDNA topoisomerase IV subunit A (ECK3010)
DNA topoisomerase IV subunit A, Bacillus anthracis ()
DNA gyrase subunit A, Bacillus anthracis ()
DNA topoisomerase IV subunit A, Legionella pneumophila ()
DNA topoisomerase IV subunit A, Neisseria gonorrhoeae ()
DNA gyrase subunit A, Neisseria gonorrhoeae ()
(gyrA, PMI1732)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

ciprofloxacin is developed for 12 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsAnthrax✓ Approved
InvestigationsBody temperature increased✓ Approved
Infections and infestationsLower respiratory tract infection✓ Approved
Infections and infestationsOsteomyelitis✓ Approved
Infections and infestationsPneumonia✓ Approved

+7 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedAAPS PharmSciTech2026-09-19

Photothermally Induced Vapor Nanobubbles Enable Disruption and Antibiotic-Improved Responsiveness in Uropathogenic Biofilms.

Alcàcer-Almansa Júlia J, Ahmad Amin A, Braeckmans Kevin K, Blanco-Cabra Núria N et al.

Treating bacterial biofilms remains a major clinical challenge, particularly in uropathogenic infections where the dense extracellular matrix impedes antibiotic access and protects tolerant bacterial populations. In this work, we explored a nanomaterial-based strategy to improve antibiotic responsiveness by combining iron oxide nanoparticles (IONPs) with pulsed laser irradiation to induce vapor nanobubble (VNB)-mediated disruption of a mature flow-grown uropathogenic E. coli CFT073 biofilm. We tested three nanoparticle sizes (70 nm, 130 nm, and 500 nm) and identified IONP500 as the most effective formulation for generating VNBs upon irradiation with 532 nm nanosecond laser pulses, with a VNB threshold of 0.56 J/cm2 per pulse. In the mature biofilm model, the combined IONP500 + ciprofloxacin + laser treatment significantly enhanced antibiotic activity compared with ciprofloxacin alone, increasing dead biomass from approximately 16% to 23%, corresponding to a 39-45% relative increase, as quantified by COMSTAT analysis and one-way ANOVA with Tukey's post-hoc test. The combined treatment also reduced total biofilm biomass and increased biofilm porosity by 55.8% compared with ciprofloxacin alone, supporting a mechanism based on VNB-mediated matrix disruption and improved antibiotic access. Overall, these results support the use of photothermally active, biocompatible IONPs as a promising complementary strategy to enhance the efficacy of conventional antibiotics against persistent biofilm-associated infections.

PubMedFrontiers in bioinformatics2026-09-18

All-atoms MD simulations study of newly designed ciprofloxacin derivatives as potential bacterial DHPS and DNA gyrase inhibitors.

Sahoo Chita Ranjan CR, Rout Madhusmita M, Paidesetty Sudhir Kumar SK, Dehury Budheswar B et al.

The widespread use of antibiotics, particularly ciprofloxacin, has accelerated the emergence of antibiotic-resistant bacteria, posing a major public health challenge. Limited investment and declining pharmaceutical interest have slowed the discovery of new antibiotics, contributing to the increasing prevalence of multidrug-resistant (MDR) infections, especially those caused by ESKAPE pathogens. Uropathogenic Escherichia coli (UPEC), a leading cause of urinary tract infections (UTIs), develops multidrug resistance through mechanisms including drug target modification and reduced antibiotic susceptibility. In the present study, a series of ciprofloxacin-sulfonamide hybrid molecules (CIS1-CIS15) was designed, in which each pharmacophore retains its established mechanism of action. Ciprofloxacin inhibits DNA gyrase and topoisomerase IV, whereas sulfonamides inhibit dihydropteroate synthase (DHPS) by competing with para-aminobenzoic acid (PABA) in the bacterial folate biosynthetic pathway. Accordingly, the designed hybrids were computationally evaluated against both enzymatic targets to investigate their potential dual-target antibacterial activity. Molecular docking and molecular dynamics (MD) simulations were performed to assess the binding affinity and stability of the ciprofloxacin-bearing sulfonamide derivatives (CIS1-CIS15) against DNA gyrase and Staphylococcus aureus DHPS. Principal component analysis (PCA) and free-energy landscape (FEL) analysis were used to characterize the conformational flexibility and low-energy states of the protein-ligand complexes, while MD simulations validated the stability of the highest-scoring docked complexes. Among the designed derivatives, CIS4 (ciprofloxacin-sulfamethoxazole), CIS5 (ciprofloxacin-sulfaguanidine), and CIS12 (ciprofloxacin-sulfamerazine) exhibited the strongest binding affinity toward both targets while maintaining conformational stability throughout the simulations. Structural analysis of the pre- and post-MD trajectories identified Arg52, Lys39, Arg88, Lys94, Lys120, Glu201, and Lys203 as key residues involved in ligand recognition. Overall, CIS4, CIS5, and CIS12 emerged as the most promising dual-target inhibitor of bacterial DHPS and DNA gyrase. These findings provide valuable structural insights for the rational design of novel fluoroquinolone-based antibacterial agents and demonstrate the utility of computational approaches in identifying potential therapeutics against drug-resistant bacterial pathogens.

PubMedFrontiers in microbiology2026-09-18

Screening of Forsythia suspensa-derived compounds identifies amentoflavone as a ciprofloxacin-potentiating candidate against MRSA.

Fang Yu Y, Yue Tianxiang T, Zhong Jia J, Zheng Hangsheng H et al.

Methicillin-resistant Staphylococcus aureus (MRSA) remains a clinically important pathogen, and bacterial efflux systems can reduce intracellular antibiotic accumulation and compromise antibacterial efficacy. NorA, a well-studied multidrug efflux pump in S. aureus, is associated with the efflux of fluoroquinolones and fluorescent substrates such as ethidium bromide (EtBr), making it a potential target for antibiotic adjuvant discovery. In this study, 100 PubChem-identifiable Forsythia suspensa (F. suspensa)-derived small molecules were screened against NorA using CB-Dock2 with AutoDock Vina scoring. Amentoflavone (AME), a naturally occurring biflavonoid, was identified as the top-ranked candidate and displayed a predicted binding pose within the NorA transmembrane cavity, with multiple potential interactions involving residues such as Thr336, Arg310, and Ser133. Molecular dynamics simulation performed using GROMACS 2025.4 further supported the dynamic stability of the predicted AME-NorA complex in a membrane-embedded environment. Functionally, AME increased intracellular EtBr-associated fluorescence in MRSA, suggesting altered EtBr-associated intracellular accumulation or efflux-associated activity. Although AME alone showed no evident direct anti-MRSA activity at concentrations up to 512 μg/mL, its combination with ciprofloxacin enhanced ciprofloxacin-mediated inhibition and killing of MRSA. Specifically, AME reduced the minimum inhibitory concentration (MIC) of ciprofloxacin from 1 to 0.5 μg/mL and the minimum bactericidal concentration (MBC) from 2 to 1 μg/mL. These findings suggest that AME may serve as a F. suspensa-derived ciprofloxacin-potentiating candidate against MRSA, potentially associated with altered efflux-related activity. Further studies using NorA genetic models, membrane permeability assays, intracellular ciprofloxacin accumulation assays, and multiple clinical isolates are needed to clarify the target specificity and broader applicability of AME-mediated ciprofloxacin potentiation.

PubMedRSC advances2026-09-18

Fabrication of a Bi-doped WO3/CFA nanocomposite for efficient photocatalytic degradation of ciprofloxacin (CIP) under visible light.

Diako Palesa P, Adeiga Opeoluwa I OI, Eswaran Prabakaran P, Pillay Kriveshini K

In this study, the synthesis of a novel bismuth-doped tungsten oxide decorated on coal fly ash (Bi-doped WO3/CFA) nanocomposite for the photocatalytic degradation of ciprofloxacin (CIP) in water was investigated. A Bi-doped WO3/CFA nanocomposite was prepared by the hydrothermal deposition of Bi-doped WO3 nanoparticles onto activated coal fly ash (CFA). Structural and morphological study of the synthesized materials was characterized using a variety of analytical techniques, which include Fourier transform infrared (FT-IR) spectroscopy, X-ray diffraction (XRD), scanning electron microscopy-energy dispersive X-ray spectroscopy (SEM-EDS) and transmission electron microscopy (TEM), BET surface area analysis, UV-vis diffuse reflectance spectroscopy (UV-DRS), zeta potential, and photoluminescence (PL). Short rod-shaped nanoparticles were successfully synthesized. A combination of the rod-shaped nanoparticles with spherical activated CFA was observed for the nanocomposite. The results showed that the nanoparticles and the nanocomposite had definite crystallinity. Tauc plot was used to calculate the band gap energies of the Bi-doped WO3/CFA nanocomposite (1.52 eV). The BET surface area of raw CFA, activated CFA, Bi-doped WO3 NPs, and the Bi-doped WO3/CFA nanocomposite was found to be 6.279 m2 g-1, 6.791 m2 g-1, 50.101 m2 g-1, and 29.452 m2 g-1, respectively. A catalyst-free environment, Bi-doped WO3 NPs, and a Bi-doped WO3/CFA nanocomposite were used for the photocatalytic degradation of CIP under visible light for 0-120 min. The nanocomposite showed better degradation of CIP than the catalyst-free environment and NPs, and this is because of its low band gap and the stability of the nanocomposite. Since the nanocomposite is a stable photocatalyst due to the synergy between Bi, WO3, and the activated CFA, it also showed an increased photocatalytic activity due to the dopant (Bi), the binary photocatalyst (WO3/CFA) and a lower band gap. A catalyst loading of 40 mg Bi-doped WO3/CFA nanocomposite and 5 ppm ciprofloxacin were optimized to obtain photocatalytic degradation of 74% under visible light irradiation for 0-120 minutes. The application was conducted varying parameters like concentration, dosage and pH, and the results indicated that the optimal conditions for the degradation of CIP (74% after 120 min) comprised a catalyst loading of 30 mg, a pH of 7 and a concentration of 5 ppm.

PubMedInternational journal of antimicrobial agents2026-09-18

Genomic epidemiology and resistance determinants of Pseudomonas aeruginosa in bronchiectasis across China: a multicentre study.

Xu Linlin L, Chen Qing Q, Ma Aikuang A, Xu Kang K et al.

To characterise the genomic epidemiology and resistance determinants of bronchiectasis-associated Pseudomonas aeruginosa in a multicentre cohort. We analysed 306 first non-duplicate P. aeruginosa isolates (2019-2021). Antimicrobial susceptibility was determined by broth microdilution and mucoid phenotype was recorded. Whole-genome sequencing was used for MLST, core-genome SNP phylogeny, resistance and virulence gene screening, and amino-acid variation in gyrA/gyrB/parC/parE, oprD, efflux regulators and mucoidy regulators (mucA, algU, mucB and mucD). Mucoid isolates comprised 68.6% of the collection. 201 sequence types indicated a polyclonal population without geographic or phenotype-specific clustering. Resistance was highest to levofloxacin (41.5%) and ciprofloxacin (39.2%), and lowest to amikacin (0.3%). Multidrug-resistant isolates accounted for 16.3%. Species-associated determinants were near-universal (blaPAO, aph(3')-IIb, fosA, catB7 and blaOXA-50), whereas acquired genes were uncommon. Among fluoroquinolone-resistant isolates, 97.0% carried amino-acid changes in at least one quinolone target gene, with canonical QRDR hotspots alongside additional variants such as gyrA (S912_E913del) and gyrB (H148N). In imipenem-resistant isolates, oprD variation was detected in 98.1% (52/53). Mucoid isolates were enriched for mucA variation (88.6% vs 57.3%). Virulence profiling revealed a largely conserved repertoire characterised by alginate regulation, quorum sensing and secreted toxins, with an exoS-predominant T3SS and broadly distributed T6SS components. Bronchiectasis-associated P. aeruginosa constitutes a polyclonal, genetically heterogeneous population. Non-susceptibility predominantly reflects intrinsic and adaptive genomic mechanisms. Given the high fluoroquinolone resistance observed, treatment should be guided by local resistance patterns and isolate-specific susceptibility results.

PubMedFrontiers in microbiology2026-09-18

Antibiotic residues and antimicrobial resistance patterns of bacteria isolated from beef at Ruti Rufura Slaughterhouse, southwestern Uganda.

Tuhamize Barbra B, Daniel Kica K

Antimicrobial use in livestock contributes to the emergence of antimicrobial-resistant bacteria and the persistence of antimicrobial residues in foods of animal origin. The coexistence of antimicrobial residues and resistant bacteria in beef poses a major food safety and public health concern. However, data on these hazards in Uganda remain limited. This study assessed antibiotic residues and antimicrobial resistance among bacteria isolated from beef marketed in southwestern Uganda. A cross-sectional laboratory-based study was conducted from May to August 2025 using beef samples from 92 randomly selected cattle carcasses at Ruti Rufura Slaughterhouse, Mbarara City, Uganda. Antibiotic residues were screened by agar well diffusion and confirmed for penicillin and oxytetracycline using thin-layer chromatography. Bacterial isolates were identified using standard microbiological methods, and antimicrobial susceptibility was determined by the Kirby-Bauer disk diffusion method according to CLSI guidelines. Antibiotic residues were detected in 86/92 (93.5%) samples. Thin-layer chromatography confirmed penicillin residues in 84 (97.7%) and oxytetracycline residues in 71 (82.6%) samples, with 73.1% containing both antibiotics. A total of 125 bacterial isolates representing seven genera were recovered, predominantly Proteus spp. (30.4%), Citrobacter spp. (26.4%), and Escherichia coli (16.8%). Among 75 viable isolates, resistance was highest to ampicillin (97.3%), chloramphenicol (86.7%), tetracycline (82.7%), ceftriaxone (57.3%), and ciprofloxacin (54.7%), while gentamicin showed the highest susceptibility (86.7%). Oxytetracycline residues were significantly associated with tetracycline resistance and penicillin residues with ampicillin resistance (both P < 0.001). Beef marketed in southwestern Uganda frequently contains antimicrobial residues and antimicrobial-resistant bacteria, posing a potential food safety risk. Strengthened antimicrobial stewardship, enforcement of withdrawal periods, and integrated surveillance of antimicrobial residues and resistance in foods of animal origin are needed to support One Health efforts against antimicrobial resistance.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about ciprofloxacin